METHODS: A retrospective analysis was performed using volumetric parameters, such as SUVmax, proliferative tumor volume (PTV), and total lesion proliferation (TLP), of pretreatment [ 11 C]4DST PET for 91 patients with HNSCC with primary lesions in the oral cavity, hypopharynx, supraglottis, and oropharynx, which included p16-negative patients. PTV and TLP were calculated for primary lesions and metastatic lymph nodes combined. We examined the association among the parameters and relapse-free survival and whether case selection focused on biological characteristics improved the accuracy of prognosis prediction.
RESULTS: The area under the curves (AUCs) using PTV and TLP were high for the oropharyngeal/hypopharyngeal/supraglottis groups (0.91 and 0.87, respectively), whereas that of SUVmax was 0.66 ( P < 0.01). On the other hand, the oral group had lower AUCs for PTV and TLP (0.72 and 0.77, respectively). When all cases were examined, the AUCs using PTV and TLP were 0.84 and 0.83, respectively.
CONCLUSIONS: Baseline [ 11 C]4DST PET/CT volume-based parameters can provide important prognostic information with p16-negative oropharyngeal, hypopharyngeal, and supraglottic cancer patients.
方法:使用体积参数进行回顾性分析,例如SUVmax,增殖性肿瘤体积(PTV),和总病变增殖(TLP),对91例口腔原发性病变的HNSCC患者进行预处理[11C]4DSTPET,下咽,声门上,和口咽,其中包括p16阴性患者。计算原发灶和转移淋巴结的PTV和TLP。我们检查了参数与无复发生存率之间的关联,以及关注生物学特征的病例选择是否提高了预后预测的准确性。
结果:口咽/下咽/声门上组使用PTV和TLP的曲线下面积(AUC)较高(分别为0.91和0.87),而SUVmax为0.66(P<0.01)。另一方面,口服组PTV和TLP的AUC较低(分别为0.72和0.77).当检查所有病例时,使用PTV和TLP的AUC分别为0.84和0.83.
结论:基线[11C]基于4DSTPET/CT体积的参数可以为p16阴性口咽提供重要的预后信息,下咽,和声门上癌症患者。